70例阿达木单抗注射液的药物不良反应报告分析

摘要

目的:探讨阿达木单抗注射液所致药物不良反应(ADR)的特点和规律,指导临床合理用药.方法:采用描述性分析的方法对2010年1月-2011年12月呈报至某省药物不良反应监测中心的阿达木单抗注射液导致的70例ADR报告进行汇总分析.结果:70例ADR报告中,男女比例1∶1；发生率较高的年龄组段为30 ～ 39岁(15例,20.43％)和0～9岁(14例,20.00％)；无合并用药情况；皮疹和谷丙转氨酶升高临床表现例数最多,分别为16例和10例；有2例死亡.结论:经文献研究,阿达木单抗注射液上报的ADR报告很少,然而严重的ADR也没有报道,因此应加强此种药物检测,以便合理用药.%To determine the characteristics and regularity of adverse drug reaction (ADR) induced by adalimumab injection so as to guide rational use of drugs. Methods: In 70 patients, adalimumab injection-induced ADRs reported in Adverse Drug Reaction Monitoring Center of a certain province from Jan. 2010 to Dec. 2011 were summarized for analysis by means of classification and description. Results: In the 70 ADR reports , the proportion of male and female was 1: 1 , a higher incidence was found in 30 ? 39 age group and 0 ? 9 age group, and no drug combination was reported. Rash (16 patients) and the rising of glutamic pyruvic transaminase (GPT, 10 patients) were relatively more frequent. Two patients died. Conclusion: Though literature research, the adalimumab injection ADRs have rarely been reported, and no serious ADR has been reported. Our results indicate that more attention should be paid to this drug monitoring in order to avoid irrational drug use.